Kook H. Kim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Novel anti-CD73-IL-2v bispecific fusion protein augments antitumor immunity by alleviating immunosuppressive adenosine pathways in CD8+ T cells.

Novel anti-CD73-IL-2v bispecific fusion protein augments antitumor immunity by alleviating immunosuppressive adenosine pathways in CD8+ T cells.

Journal: Journal for immunotherapy of cancer

Published: February 26, 2025

Discovery of a selective cytochrome P450 4A inhibitor for the treatment of metabolic dysfunction-associated fatty liver disease.

Discovery of a selective cytochrome P450 4A inhibitor for the treatment of metabolic dysfunction-associated fatty liver disease.

Journal: Clinical and translational medicine

Published: December 01, 2023

Phosphorylation of EIF2S1 (eukaryotic translation initiation factor 2 subunit alpha) is indispensable for nuclear translocation of TFEB and TFE3 during ER stress.

Phosphorylation of EIF2S1 (eukaryotic translation initiation factor 2 subunit alpha) is indispensable for nuclear translocation of TFEB and TFE3 during ER stress.

Journal: Autophagy

Published: January 31, 2023

Cell non-autonomous effect of hepatic growth differentiation factor 15 on the thyroid gland.

Cell non-autonomous effect of hepatic growth differentiation factor 15 on the thyroid gland.

Journal: Frontiers in endocrinology

Published: June 11, 2022

Snail acetylation by autophagy-derived acetyl-coenzyme A promotes invasion and metastasis of KRAS-LKB1 co-mutated lung cancer cells.

Snail acetylation by autophagy-derived acetyl-coenzyme A promotes invasion and metastasis of KRAS-LKB1 co-mutated lung cancer cells.

Journal: Cancer communications (London, England)

Published: December 03, 2021

GDF15 as a central mediator for integrated stress response and a promising therapeutic molecule for metabolic disorders and NASH.

GDF15 as a central mediator for integrated stress response and a promising therapeutic molecule for metabolic disorders and NASH.

Journal: Biochimica et biophysica acta. General subjects

Published: May 21, 2020

Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH).

Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH).

Journal: International journal of molecular sciences

Published: March 06, 2020

TFEB-GDF15 axis protects against obesity and insulin resistance as a lysosomal stress response.

TFEB-GDF15 axis protects against obesity and insulin resistance as a lysosomal stress response.

Journal: Nature metabolism

Published: October 24, 2019

An autophagy enhancer ameliorates diabetes of human IAPP-transgenic mice through clearance of amyloidogenic oligomer.

An autophagy enhancer ameliorates diabetes of human IAPP-transgenic mice through clearance of amyloidogenic oligomer.

Journal: Nature communications

Published: September 28, 2018

Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches.

Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches.

Journal: Frontiers in endocrinology

Published: April 30, 2018

Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.

Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.

Journal: Scientific reports

Published: October 04, 2017

Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition.

Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition.

Journal: Autophagy

Published: September 22, 2017

Showing 1-12 of 23

Last Updated: 09/26/2026